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Recent epidemiologic studies have shown that in patients with acute respiratory tract infection, intracellular pathogens, 
and particularly Mycoplasma pneumoniae and Chlamydia pneumoniae, might be involved more frequently than was 
previously assumed. In addition, newer investigations, such as specific culture or polymerase chain reaction (PCR), when 
systematically performed in patients with asthma, chronic obstructive pulmonary disease and even cystic fibrosis, 
frequently detect Mycoplasma pneumoniae or Chlamydia pneumoniae in those individuals. The significance of such 
detection (chronic bronchial infection?) and the role that these intracellular pathogens might play in the natural history 
of chronic respiratory diseases remain to be evaluated. 
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~\fyi-oplasriza pneirrnoniae [ 11, Chlamydia psittari, Coxiella 
hirrrietti 121, Lefionella spp. [3]  and, more recently, 
Clllarnydia prwrrrnorziae [4] have all been recognized as 
pathogens possibly responsible for pneumonia 151. 
przeiirnorziae and Chlamydia prietrinoriiae infections have 
alro been incriminated as possible causes of acute 
bronchitis or exacerbation of chronic bronchitis or 
chronic obstructive pulmonary disease (COPD) (61. 
However, the incidences of these intracellular pathogen 
infections in patients with acute lower respiratory tract 
infection have varied with the investigations used and 
the criteria involved in their diagnosis. The more 
recent use of specific culture or polymerase chain 
reaction (PCR) for detection of M. pHeumoniae or 
Chlurnydia pneumoniar might considerably modify 
existing epidemiologic data resulting from previous 
studies. Moreover, the detection of these intracellular 
pathogens in patients with asthma or COPD suggests 
that they might play a role in the natural history ofthese 
chronic respiratory diseases [7] .  
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EPIDEMIOLOGY OF INTRACELLULAR PATHOGENS IN 
COMMUNITY-ACQUIRED PNEUMONIA 
Epidemiology in patients with community-acquired 
pneumonia treated at home 
For practical reasons it is difficult to perform epideniio- 
logic studies in patients treated a t  home. The method? 
used frequently involve measurement of serum anti- 
bodies or antigens. Excluding one recent investigation 
[S] M.  przeurnoniae infection, defined by microbiological 
criteria, has been found in 8-37% of cases (Table 1). 
Legionella infection way very low except in one of the 
two Spanish investigations [lo]. Thr  incidence of 
chlamydia1 infection was also very low when specific 
antibodies were detected with a coiiipleiiieiit-fi>;atioii 
test 18.91. In contrast, in recent investigations the 
incidence of Clilarnydia prieclriioriine infection was 
between 12% and 15% when antibodies were detected 
with the inicroiiiiniunofluoresce~ice test [12-I 41. 
Epidemiology in patients with community-acquired 
pneumonia treated in hospital 
111 patient? with niore ?evere community-acquired 
piieumonia tieated in hospital, the incidence of M 
pneirrizonm infection remained around 15% in four 
seriec 115-181, around 20% in five seriec [19-23) aiid 
even reached 29% [24] I n  contiast, in the same wries, 
Legiorrella prrauvnopliila was more frequent than in 
4S14 
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patients treated at home [17,24-281. In 13 studies using 
a complement-fixation test (Table 2), chlamydial infec- 
tions were diagnosed in less than 3% of patients, if we 
except the results of Chang in Hong Kong [30]. 
However, in eight series using the microimmuno- 
fluorescence test, microbiological diagnosis of Chlamydia 
pneumoniae infection increased to more than 5%, except 
in studies by Karalus et a1 [22] in a small number of 
patients (Table 3 ) .  Finally, when different methods were 
used simultaneously [18,23,24,35] the incidence of 
Chlamydia pneumoniae infection, like that of M. 
pneumoniae infection, reached 10-20%. Such data were 
reported by Blasi et al[18], who used serologic tests and 
also pharyngeal swab examination, and in the series by 
Lieberman et al [24] who used serologic tests to detect 
specific IgM, IgG and also IgA. 
Epidemiology in patients with community-acquired 
pneumonia treated in an intensive care unit 
In patients with the most severe community-acquired 
pneumonia treated in an intensive care unit, the 
incidence of M. pneumoniae appears to be less than 3%. 
Legionella species play an important role in some 
countries, e.g. Spain [36-381. Chlamydia species were 
Table 1 
Reference No. of patients Chlamydia spp. M. pneumoniae Legionella spp. Coxiella burnetii Undetermined etiology 
Intracellular pathogens associated with community-acquired pneumonia treated at home (“A of cases) 
[81 236 1% 1 0.5 0 45 
[91 54 4” 37 0 N T  41 
1101 48 2 a  13 12 0 42 
1111 161 6 17 2 2 47 
1121 76 12b 22 1 N T  35 
~ 3 1  105 15‘ 8 3 0 57 
1141 149 15‘ 25 1 3 48 
aComplement-fixation test. bMicroimmunofluorescence assay. NT, Not tested 
Table 2 
Reference No. of patients Chlamydia spp. M.  pneumoniae Legionella spp. Coxiella burnetii Undetermined etiology 
Intracellular pathogens associated with community-acquired pneumonia treated in hospital (“A of cases) 
[I51 210 1 14 1 3 52 
1161 127 2” 14 1 1 27 
1171 255 3 b  16 11 N T  29 
~191 314 N T  24 3 2 33 
1201 453 3“ 18 2 1 33 
1251 400 2.8 2.3 7.5 N T  59 
1261 274 3 9 9 1 49 
1301 90 b6 3 0 0 59 
[211 106 1“ 22 0 N T  14 
~291 147 1” 5 1 N T  29 
~311 254 1” 4 3 0 66 
[321 165 1 10 3 11 29 
1331 334 3 6 2 0.3 45 
*Complement-fixation test. bELISA. NT. Not tested. 
Table 3 Intracellular pathogens associated with community-acquired pneumonia treated in hospital (% of cases) 
Reference No. of patients Chlamydia spp. M.  pneumoniae Legionella spp. Coxiella burnetii Undetermined etiology 
108 
92 
93 
346 
359 
154 
301 
236 
13‘ 
2 b  
20” 
18“ 
6a 
5b 
6a 
11” 
14 
18 
1 9d 
29 
2 
2 
3 
9 
NT 
N T  
2 
6 
N T  
NT 
2 
2 
46 
33 
17 
19 
33 
49 
37 
32 
”Microinmunofluorescence test (MIF). bMIF + culture. ‘MIF + indirect immunofluorescence test on pharyngeal swab. 
dIrnmunofluorescence test + PCR (sample obtained by transthoracic needle aspiration). NT, not tested. 
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Table 4 Intracellular pathogens associated with severe coniiiiunityacquired pneumonia ("9 of ca<es) 
~~~ ~~ 
Reference No. o f  patients Chlamydia spp. M .  prieumoriiae Lqimiel la  spp. Coxielln birrrietii Undetermined etiology 
1361 67 (I'aOr<hO) 0 2  0 22 0 
~ 7 1  3x (1C:u) 0' 0 14 0 
13x1 362 ( ICU)  - 7'? 3 8 0 
13"1 52 (ICU) NT 2 29 NT 
1401 129 (CV) NT 3 2 I 
[411 132 (ICU) 1 1 3 - 7
1421 61 (PaCh<hO) 10" 2 3 NT 
.5 2 
40 
41 
18 
27 
37 
i l  
,'Conipleiiient-fixatiori test. 
"Microimmunofluorescencc test + Indirect ininmunofluorescence tcst on pharyngeal swab 
CV. controlled ventilation; ICU,  intenrive care unit. 
seldom present when a cotiiplement-ilxation test was 
used for diagnosis (Table 4). However, the incidence of 
this infection might be higher if the micro- 
inimunofluorescence test was used [42]. 
FACTORS INFLUENCING THE INCIDENCES OF 
INTRACELLULAR PATHOGEN INFECTIONS IN 
PNEUMONIA 
PATIENTS WITH COMMUNITY-ACQUIRED 
Analysis of Tables 1-4 shows clearly that the nieasured 
incidences vary with the diagnostic test used for 
microbiological diagnosis, particularly for Clilarnydiu 
pneumoniae infection. Similarly, these tables illustrate the 
variations in incidences according to the severity of 
pneumonia. Another factor which plays an important 
role in determining the incidences observed in patients 
treated in hospital is the use of previous antibiotic 
therapy. In a study by the British Thoracic Society, ,V. 
prieurnoriiae was responsible for 44.8% of microbio- 
logically documented pneumonia in patients who had 
undergone previous antibiotic therapy but for only 
5.6% in patients who had not [20]. 
The age of patients is another factor influencing 
the incidence of intracellular pathogen infections. In 
children with pneumonia, the incidence of M.  pneu- 
rnoniae is particularly high [I 6,431 between 18%) [44] 
and 40% [451. The incidence of chlamydia1 infection is 
very low with the complement-fixation test and 
remains low for Chlamydia pneumoriiae with micro- 
ininiunofluorescence [44]. However, this incidence 
niight be higher if we considered the series by Block 
[43], who used serologic tests and also nasopharyngeal 
culture. In the elderly with pneumonia, the opposite 
pattern is observed [31]. The incidence of M .  yueu- 
rnoniae infection is very low, less than 5% [24,46,47]. In 
contrast, the incidence of Chlamydia pueumoniac is 
around 10%1 [47], or 20%) [lS] with the immuno- 
fluorescence test. 
The frequencies observed also vary with the place 
and time of study. Three examples illustrate such varia- 
tions according to place. The incidence of Lqiorielh 
pneurnopliila pneumonia is particularly high in Spain 
(Tables 1-4). There was also a high incidence (up to 
19% in 1985) of Q fever pneumonia in the Basque 
country. Also relevant are the results of a recent Italian 
study performed in four sites (Chieti, Genoa, Catania 
and Rome) during the same year with the 'ianie 
investigations. The incidence of Clilnniydiu prreirrrioniuP 
infection varied between towns from 2% to 20'36, that 
of M .  prieuriioriiae from 3%) to 20%. and that of legion- 
ella pneumonia from 3% to 16% [48]. A good illustra- 
tion of variation with regard to tinie is provided by 
studies performed by the same team, at  the same site, 
with similar investigations. McFarlane et a1 [49] and 
Woodhead et al [8] showed a variation in the incidence 
oflegionella pneumonia from 13% in 1980-81 to 0.5% 
in 1984-85. The studies by Fernald and Clyde [50] also 
show an important variation in the incidence of M .  
pneunioniae pneumonia from 51 % in 1965-69 to 13% 
in 1984-87. Grdyston et a1 [5l] found a similar 
variation in the incidence of Clilarriydia pneurrioniac 
pneumonia due to an outbreak: 5% in 1986-90 and 
44% during November 1990 to February 1991. 
However, it should be noted that if we except 
outbreaks observed with M.  pneurnoniae [52] and 
Chlairiydia pneumoriiur [53], some authors found little 
variation with season or year at the same site [34]. 
EPIDEMIOLOGY OF INTRACELLULAR PATHOGENS IN 
OTHER ACUTE RESPIRATORY INFECTIONS 
Epidemiology in patients with acute bronchitis 
Few studies have been perfornied in adults or children 
with acute bronchitis. It  is currently believed that 
viruses are usually the cause, but antibiotics are 
frequently prescribed in such clinical situations [55,56]. 
With appropriate serologic tests, Chlamydia pnerrmouiac 
and 114. pneurnoniae were found in 5% of cases (Table 5) 
[ 11,5 1 ,581. More recent studie? in children using 
serologic tests, culture and/or PCR have detected 
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Table 5 
(% of cases) 
Intracellular pathogens associated with acute bronchitis Table 6 
tract infection (% of cases) 
Intracellular pathogens associated with upper respiratory 
No. of Chlamydia M.  
Reference patients pneumoniae pneumoniae 
No. of Chlamydia M. 
Reference patients pneumoniae pneumoniae 
[12] 1983-85 63 5 b  3 
[44]" 1992-94 39 15" N T  
[51] 1990-91 22 18 18 
[57]" 1992-93 82 NT 6d 
[59] 1992 96 >20' 2 
[51] Pharyngitis 300 0.3a N T  
[51] Sinusitis 89 3.4" N T  
[57] Common coldd 155 N T  0.6 
[57] Laryngitisd 13 NT 0 
[61] Pharyngitis 106 8.5b 9' 
children. 
hMicroimmunofluorescence (MIF) + direct fluorescent-antibody 
technique (DFA) + culture. 
'MIF + PCR+ culture + IDEIA Chlamydia kit. 
dMIF + PCR + culture. 
eMIF (IgG, IgM, IgA) + culture. 
NT, not tested. 
M.  pneumoniae in 6% of cases [57] and Chlamydia pneu- 
moniae in 15% [44]. Moreover, during one epidemic, 
these intracellular pathogens were associated with acute 
bronchitis in 36% of cases [51]. Falck et al [59] have also 
found a very high incidence of Chlamydia pneumoniae 
infection in adults with acute bronchitis but these 
results have been questioned by Ortquist with respect 
to the particular criteria for patient selection (symptoms 
for >l week), the debatable criteria for serologic 
diagnosis and the absence of exhaustive microbiological 
investigations to detect mixed infections [60]. 
Epidemiology in patients with upper respiratory tract 
infection 
Few studies have been performed in adults or children 
with pharyngitis, sinusitis, laryngitis or the common 
cold. In these series, Chlamydia pneumoniae or M. 
pneumoniae infections were usually associated with only 
0-4% of cases [51,57]. However, in a study using 
culture, a microimmunofluorescence test and an 
immunoassay, Huovinen et a1 [61] incriminated both 
agents, each in 9% of cases of pharyngitis (Table 6). 
Epidemiology in patients with exacerbation of chronic 
bronchitis and/or chronic obstructive lung disease 
The difficulties of interpretation and comparison of the 
"Microimmunofluorescence (MIF) + DFA + culture. 
'ME 
'Enzyme immunoassay. 
children. 
NT, not tested. 
results of microbiological studies in these patients have 
been well discussed by various authors. There are 
differences in clinical criteria used to define exacerba- 
tion; differences in microbiological investigations used 
to establish an infectious cause; and, finally, difficulties 
in interpreting the results of these microbiological 
investigations. As an example, investigations have found 
bacteria at  2103 CFU/mL in distal bronchial airways of 
50% of patients with exacerbation but also in 25% of 
controls with stable COPD [62,63]. In recent studies, 
serologic criteria have identified acute M .  pneumoniae 
or Chlamydia pneumoniae infection in only 0-5% of 
patients (Table 7). These incidences were not higher 
with the use of DNA probes for M.  pneumoniae and 
Legionella pneumophila on selected specimens [66] or 
with the use of culture to detect Chlamydia pneumoniae 
[67]. Blasi et a1 [68] found a high level of Chlamydia 
pneumoniae-specific IgG (r1/512) in 14% of patients 
with exacerbation of COPD. However, they found 
similar levels in 5% of control subjects without history, 
signs or symptoms of pulmonary disease. They 
concluded that at least 4% of exacerbations may be 
associated with Chlamydia pneumoniae infection [68]. 
In Beaty's series, serologic criteria for current or 
recent Chlamydia pneumoniae infection, defined by an 
IgM titer of >1/16 or an IgG titer of 21/512, were 
Table 7 Intracellular pathogens associated with exacerbation of chronic obstructive pulmonary disease ("3 of cases) 
~~~ 
Reference No. of patients 
~ ~ 
Chlamydia spp. A4 pneumoniae Legionella spp Coxiella burnetii 
N T  2.4 N T  
N T  0.5 N T  
n nb 0' 
5" N T  N T  
>4%d n 0 
N T  
N T  
N T  
N T  
N T  
'Microimmunofluorescence (MIF) + culture. 
b!3NA probe. 
'DFA/DNA probe. 
"MIF + IFA test (oropharynx). 
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present in only 5% of patients with COPD and 
exacerbation. Such current or recent infection was not 
observed in control subjects with stable COPD but was 
present in 8% of control subjects without COPD [67]. 
In Buscho's series [64], hL pneumoniae infection was 
identified by serologic criteria in 2.4% of patients with 
chronic bronchitis and exacerbation and in 0% of the 
same patients without exacerbations 1571. Finally, 
Smith et a1 have found 144. pneumoniae infection in 0.5% 
of patients with COPD whether or not there was 
superimposed acute respiratory illness [65]. 
In patients with COPD and pneumonia, Torres et 
a1 found incidences of Chlamydia pneurnoniae and 
Mycoplasnia pnetrmoniae infection of respectively, 3% and 
7% [69]. Such incidences were similar to those 
observed in patients without COPD. 
Epidemiology in patients with other lower respiratory tract 
infections 
Chlamydia pneumoniae and M.  pneumoniae [7O], Lqionel la  
species [3] and Cmielln burrzetii [2] have all been 
recognized as possible causes of small pleural effusion 
171 or bronchiolitis obliterans organizing pneumonia 
[72]. They may also be responsible for pneumonia in 
inmunocompromised patients, particularly Legionella 
species in organ transplant recipients and Chlamydia 
przetrmoniae in HIV-infected patients [73,74]. 
Legioriella species and, to a lesser degree, Chlamydia 
prieumoniae are also responsible for nursing home- 
acquired lower respiratory tract infection [75,76] and 
for nosocomial pneumonia [77,78]. Finally, using 
specific cultures in patients with cystic fibrosis, Emre 
et a1 have recently isolated Chlamydia pneumoniae in 
12.5% of patients with acute pulmonary exacerbation 
and 0% of clinically stable patients [79]. 
ROLE OF INTRACELLULAR PATHOGENS IN 
RESPIRATORY DISEASES 
In the majority of cases, particularly in patients with 
symptoms and signs of acute respiratory infection, there 
is evidence that an intracellular pathogen diagnosed by 
microbiological criteria i s  responsible. I n  a recent 
outbreak reported by Grayston [51], it was apparent 
that Chlamydia ynenmoniae caused pneumonia and 
bronchitis. There were clear clinical criteria of acute 
respiratory infection and clear microbiological criteria 
of acute Chlaiiiydia pneumoniae infection with close 
correlation between PCK demonstration of Chlamydia 
pncnmorziae and microinimunofluorescence serolog7 
results. When Chlamydia pnrumoriiae infection was 
found, there was no evidence of other respiratory 
pathogens. Finally, the evolution of all patients with 
Chlamydia pneurnoniae infection was favorable with 
erythromycin or tetracyclines. In such cases, partic- 
ularly in cases of pneumonia, animal models [80] and 
human bronchoalveolar lavage data suggest the involve- 
ment of an immunologic mechanism. 
In three other situations, particularly when Cliln- 
mydia pneumoniae or '44. pwrnon iae  are present, the role 
of intracellular pathogen5 i$ less clear. The first is the 
case of patients with symptoms and signs of acute 
respiratory infection, where an intracellular infection is 
diagnosed but is associated with another pathogen. 
Frequently, one or both infections are microbio- 
logically defined by serologic criteria. Such is the case 
in the series by Kauppinen et al, where Clilarnydia 
yneirmorziae was frequently associated with Streptococciix 
yrzeirrnoniae in patients with pneumonia [53]. Such 
associations have also been reported for Chlamydia 
pneurnoniae [81] and M.  pneirmoniae [82], in inimuno- 
compromised patients (731 or in patients with cystic 
fibrosis [79]. In such cases, where two pathogeus are 
associated, there are three main hypotheses. 
Associations niay result from: 
false positivity due either to carriage or to an 
error in interpretation of serology results; 
bacterial colonization or infection super- 
imposed on chronic intracellular pathogen 
infection, particularly in patients with COPD; 
acute bacterial infection superimposed on 
acute intracellular pathogen infection, particu- 
larly in patients without underlined respiratory 
disease. 
In the case of patients with COPD, without acute 
events, in which an  intracellular pathogen is detected 
by PCK, the question is how to interpret this positive 
PCR. I n  adults with pneumonia and without COPD. 
positive 224. pnenmoniae or Chlamydia pneisrnoniae PCK 
seems to be clearly correlated with resulting acute 
respiratory infection (23, 831. In contrast, in patients 
with COPD, Blasi et a1 found positive Clzlumydia 
pneumoniae PCR in 26% of patients with no 
exacerbation [84]. Similarly, Von Hertzen et a1 [85] 
found positive Chlamydia pneumoniac PCR in 40%) of 
patients with moderate COP11 (FEVI 250% of the 
predicted value). 111 such cases, positive PCR might 
reflect either intermittent carriage or chronic bronchial 
infection [861. 
Von Hertzen et a1 [ 83 have compared different 
markers of Clzlamydin p m r m o n i n c  infection in patients 
with COPD of various degrees of severity and in 
patients with pneumonia. Circulating specific immune 
complexes, specific secretory IgA (sIgA) in sputum, 
positive specific PCR in sputum and high levels of 
specific IgA in serum were present in a small percentage 
of patients with pneumonia and in a high percentage 
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of patients with COPD, particularly those with severe 
COPD. Serologic markers, including circulating 
immune complexes, were stable for several months. In 
contrast, changes in the presence of sputum sIgA or in 
PCR positivity were frequently observed between 
paired specimens. Von Hertzen et a1 concluded that, in 
patients with COPD, positive P C R  more probably 
reflects a chronic Chlamydia pneumoniae infection. They 
propose, as microbiological criteria of such chronic 
infection, positivity of two of the following three tests: 
PCR,  serum microimmunofluorescence (IgG 2128 
and IgA 240) and sputum sIgA enzyme immunoassay 
Acute or chronic infection due to intracellular 
pathogens might induce superimposed bacterial 
colonization [78] and infection, because of their 
harmful effects on ciliated bronchial epithelial cells [87] 
and, to a lesser degree, neutrophils [88] and alveolar 
niacrophages. Similarly, chronic infection due to 
Chlamydia pneumoniae or M.  pneumoniae might modi6 
the natural history of chronic bronchitis and COPD by 
a vicious circle resulting from four mechanisms: 
P51. 
1. A chronic superimposed bacterial colonization 
as suggested by a recent study [84]. 
2. A persistent local immune response with cyto- 
lytic activity of CD8 lymphocytes and/or 
production of cytokines. 
3. A resulting chronic inflammation. 
4. A stimulation of IgE production leading to 
airways reactivity and bronchospasm. 
The third of these mechanisms may occur in the case 
of patients with asthma. Intracellular pathogens could 
play a role in the initiation and exacerbation of asthma 
[89]. Cases are reported of associations between acute 
Chlamydia pneumoniae or M .  pneumoniae infection and 
onset of asthma [90,91]. Other results show an 
association between acute Chlamydia pneumoniae or M. 
pneumoniae infection and exacerbation of asthma 
190,921. Results of prospective studies show acute 
infection with intracellular bacteria in 11% of adults 
with acute exacerbation of asthma [93] and 11% of 
children with acute episodes of wheezing [94]. Finally, 
results of a recent case-control study show a higher 
prevalence of Chlamydia pneumoniae-specific IgA titers 
210 in adults with recently diagnosed asthma 1951. 
However, the actual role that these intracellular 
pathogens play in asthma initiation or exacerbation 
remains to be determined. 
Intracellular pathogens could also play a role in the 
promotion of asthma [89], if we consider the recent 
demonstration of acute or chronic bronchial infection 
by Chlamydia pneumoniae, and, to a lesser degree, M.  
pneumoniae in some asthmatic patients. In a case-control 
study performed in adults with acute respiratory illness, 
Hahn et a1 [90] have shown a strong quantitative 
association of Chlamydia pneumoniae antibodies at high 
titer with the presence of wheezing after respiratory 
illness. In another study performed in similar patients, 
they found a relationship between Chlamydia pneu- 
moniae antibodies at high titer and diagnosis of acute 
asthmatic bronchitis or underlying chronic asthma [96]. 
Gill et al 1971 detected M.  pneumoniae by culture of 
throat swabs in 24.7% of children and adults with 
asthma, while the isolation rate was 5.7% in controls. 
Emre et a1 [94] and Cunningham et al [98] respectively 
detected Chlamydia pneumoniae by culture or PCR in 
nasopharyngeal specimens in 11% and 46.9% of 
symptomatic asthmatic children. Such positive culture 
was detected in only 4.9% of healthy children in a 
control group [94]. However, it should be noted that 
Cunningham et al found an associated pathogen in 72% 
of symptomatic asthmatic children with positive 
Chlamydia pneumoniae P C R  and a positive Chlamydia 
pneumoniae P C R  in 27.7% of asymptomatic asthmatic 
children. 
A role for intracellular pathogens in asthma is also 
suggested by the demonstration of a specific IgE 
response to 211. pneumoniae or Chlamydia pneumoniae 
infection 192,991 and the relative effectiveness of 
tetracyclines or macrolides in asthmatic patients with 
intracellular pathogen infection [90,100,101]. In 1994, 
Yano et a1 1911 found a relationship between the 
detection of M.  pneumoniae-specific IgE and the 
presence of persistent cough after pneumonia due to 
this pathogen. In one of these patients, a bronchial 
inhalation challenge test with partially purified M.  
pneumoniae antigen yielded a positive result. Moreover, 
Emre et al [99] detected specific Chlamydia pneumoniae 
IgE in 85.7% of asthmatic children with acute episodes 
of wheezing and positive Chlamydia pneumoniae culture. 
In contrast, such IgE was detected in only 9% of 
children with pneumonia and positive Chlamydia 
pneumoniae culture without wheezing and in only 18% 
of asthmatic children with acute exacerbation but with 
negative Chlamydia pneumoniae culture [99]. This 
production of IgE is a possible mechanism through 
which Chlamydia pneumoniae and M. pneumoniae might 
trigger allergic sensitization and develop airways 
hyperresponsiveness [91]. 
Finally, in patients with chronic asthma and micro- 
biological criteria for Chlamydia pneumoniae infection, 
three studies have shown the relative effectiveness of 
tetracyclines or macrolides. In an open label trial, Emre 
et a1 1941 treated 12 asthmatic children with acute 
episodes of wheezing and positive Chlamydia 
pneumoniae culture with macrolides and observed a 
symptomatic and FEVl improvement in 75% of cases. 
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However, there was no control group of untreated 
children. In a second open label trial, Hahn et al [loo] 
treated 42 adults with moderate to moderately severe, 
stable, chronic asthma, seropositive for Chlamydia 
pneumoniae, with doxycycline or macrolides. He  found 
a ‘cure’ or significant improvement of asthma in 
approximately half of the patients. This improvement 
was more likely in patients with early disease and before 
the development of fixed obstruction. In a final study, 
Black et a1 [ loll  observed a number of patients with 
poorly controlled asthma who were treated with 
macrolides and whose asthma improved substantially. 
CONCLUSIONS 
The role played by intracellular pathogens in acute 
respiratory tract infection is probably more important 
than previously believed but must be re-evaluated with 
the use of newer validation methods. 
There is a strong association between intracellular 
pathogens and both asthma and COPD. However, 
although seroepidemiologic and microbiological studies 
support a potential role for Chlamydia p n e u m o h e  and, 
to a lesser degree. M .  pneumoniae in asthma and COPD, 
a causal relationship remains to be confirmed. There 
are two ways to progress: to continue biological and 
experimental approaches and also to carry out 
randomized therapeutic trials, if we believe that there 
are enough data to justify them 
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